Research Papers:

Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014

Yijun Jia, Chenbo Sun, Zebing Liu, Weige Wang and Xiaoyan Zhou _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:3956-3967. https://doi.org/10.18632/oncotarget.23285

Metrics: PDF 1986 views  |   HTML 2498 views  |   ?  


Yijun Jia1,2,3, Chenbo Sun1,2,3, Zebing Liu1,2,3,4, Weige Wang1,2,3 and Xiaoyan Zhou1,2,3

1Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

3Institute of Pathology, Fudan University, Shanghai 200032, China

4Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China

Correspondence to:

Xiaoyan Zhou, email: [email protected]

Keywords: breast lymphoma, diffuse large B-cell lymphoma, incidence, survival

Received: June 29, 2017     Accepted: September 20, 2017     Published: December 08, 2017


Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin’s lymphoma with limited data. In this study, a population-based study of primary breast DLBCL in the United States was performed to determine its incidence trends, prognostic factors, survival, the role of surgery as well as the comparison with nodal DLBCL. 1021 patients diagnosed with breast DLBCL were identified in the Surveillance, Epidemiology, and End Results (SEER) cancer registries from 1973–2014. The incidence of both breast and nodal DLBCL increased over time. Patients with breast DLBCL were older, mainly women, diagnosed at earlier stages and had lower prevalence in white and black races compared with nodal DLBCL. Multivariate analysis revealed older age (≥ 70 years old) and advanced stage as independent predictors of worse OS. Independent predictor of better DSS were younger age (< 70 years old), early stage and diagnosis after 2000. When analyzed according to age, stage, race, tumor laterality and year of diagnosis, the overall survival did not benefit from surgery except in patients diagnosed between 2001–2010 and the surgery rate decreased overtime. Compared with nodal DLBCL, breast DLBCL patients exhibited a better outcome. In conclusion, breast DLBCL is a rare tumor with increasing incidence and improved survival over the last four decades. The introduction of rituximab seems to improve the outcome of breast DLBCL. Further studies are needed to advance our understanding of breast DLBCL and optimize the treatment strategy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23285